IMTX Immatics Biotechnologies Company Short-Term Debt

Immatics - graphic logo of issuer IMTX

This price chart for Immatics N.V. (IMTX) reflects the performance of a company that has developed a unique TCR-T technological framework with proprietary target discovery systems. The business is capitalized through substantial payments from pharma behemoths and future licensing fees, with the indicator standing at 0.00. The growth strategy relies on global alliances to capture massive demand within the innovative tumor treatment segment.

IMTX immatics.com Short-Term Debt (07/04/2022 - 10/30/2026)

Analytical breakdowns and data insights for company Immatics Biotechnologies (IMTX)

- current quotes and average value forecast:
Price Chart Immatics|IMTX - Average Forecast Price
- market capitalization data:
Market Value Immatics N.V.|IMTX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Immatics|IMTX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio immatics.com|IMTX - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Immatics N.V.|IMTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Immatics N.V.|IMTX - Aggregate Debt Obligations|Debts to Book Capitalization Immatics N.V.|IMTX - Long-Term Debt Volume|Company Short-Term Debt Immatics|Quick Liquidity immatics.com
- earnings and multiples data:
IMTX - Net Income
General company analysis:Immatics (IMTX)
Flagship merchandise of immatics.com

To assess the stability of Immatics N.V. (IMTX), it is critical for investors to understand the business's liquidity structure. The development of T-cell therapies and the expansion of the ACTengine platform require significant capital expenditures. The trend in total current liabilities reflects the volume of debt due within the next twelve months. An increase in this metric amid high Fed rates raises the cost of debt servicing. Controlling these liabilities confirms the financial reliability of the asset.

Competitors of Immatics N.V.

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Xencor Inc (XNCR) - Short-Term Indebtedness|Compass Bio - Company Current Liabilities|Replimune Inc. (REPL) - Short-Term Debt|LYEL: Company Current Liabilities|Company Short-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Short-Term Debts|CGEN - Short-Term Debt Volume|Company Short-Term Debt IO Biotech Corp|Company Current Liabilities Sutro Biopharma, Inc (STRO)|Company Short-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)